| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $350.02B | +13.9% |
| Cost of Revenue | $146.31B | +9.7% |
| R&D Expense | $49.33B | +8.6% |
| SG&A Expense | $14.19B | -13.6% |
| Operating Income | $112.39B | +33.3% |
| Pre-tax Income | $119.81B | +39.8% |
| Income Tax | $19.70B | +65.2% |
| Net Income | $100.12B | +35.7% |
| EPS (Basic) | $8.13 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $23.47B | -2.4% |
| Short-term Investments | $72.19B | -16.9% |
| Accounts Receivable | $52.34B | +9.1% |
| Current Assets | $163.71B | -4.6% |
| Total Assets | $450.26B | +11.9% |
| Current Liabilities | $89.12B | +8.9% |
| Long-term Debt | $12.00B | -19.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $125.30B | +23.1% |
| Capital Expenditures | $52.53B | +62.9% |
| Investing Cash Flow | -$45.54B | -68.3% |
| Financing Cash Flow | -$79.73B | -10.6% |
| Free Cash Flow | $72.76B | +4.7% |
| +39.2% |
| EPS (Diluted) | $8.04 | +38.6% |
| Total Liabilities |
| $125.17B |
| +5.2% |
| Stockholders' Equity | $325.08B | +14.7% |